Biotech entity
pharma is the sole category represented across all 1 tracked stories. CSL Behring is most often covered alongside Grifols, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention CSL Behring, all published on February 20, 2026.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. CSL Behring is most often covered alongside Grifols, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention CSL Behring, all published on February 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CSL Behring. Shared-story counts are live from our verified record — not editorial picks.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by massive investments in plasma collection infrastructure and rising demand for primary immunodeficiency treatments. This growth reflects a stabilization of the supply chain following pandemic-era disruptions and a strategic shift toward subcutaneous delivery methods.
CSL Behring is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
